<DOC>
	<DOCNO>NCT01150097</DOCNO>
	<brief_summary>The reason extension evaluate long-term safety efficacy two concentration-controlled everolimus regimen de novo liver transplant recipient . The important long-term safety assessment include evaluation renal function , progression HCV relate allograft fibrosis , treatment related effect Month 36 post-transplantation compare extension baseline ( Months 24 post-transplantation ) .</brief_summary>
	<brief_title>Extension Study Evaluate Long-term Efficacy Safety Everolimus Liver Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Written inform consent Ability willingness adhere study regimen Completed core study assign regimen ; Patients fulfil follow criterion eligible inclusion study : Severe hypercholesterolemia hypertriglyceridemia . Low platelet count . Low white blood cell count . Positive test human immunodeficiency virus ( HIV ) . Systemic infection require active use IV antibiotic . Patients critical care set . Use prohibit medication . Use immunosuppressive agent utilized protocol . Hypersensitivity study drug similar drug . Pregnant nursing ( lactate ) woman Women childbearing potential use highly effective method birth control . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Liver transplantation</keyword>
	<keyword>Everolimus</keyword>
	<keyword>Calcineurin inhibitor</keyword>
	<keyword>Tacrolimus</keyword>
	<keyword>Renal function</keyword>
	<keyword>Progression HCV relate allograft fibrosis</keyword>
</DOC>